Associação para Investigação e Desenvolvimento da Faculdade de Medicina

Their core work

AIDFM is the research and development association of the University of Lisbon's Faculty of Medicine, channeling clinical research capabilities into European health projects. They specialize in clinical trials, cardiovascular disease research, and digital health solutions for patient monitoring. Their work spans from drug development trials (such as testing beta3-adrenergic receptor agonists for cardiac hypertrophy) to building pan-European networks for paediatric clinical trials. They bring clinical infrastructure and medical expertise to large consortia tackling chronic diseases, mental health comorbidities, and ICU-level telemedicine.

What they specialise in

How they've shifted over time

AIDFM's early H2020 work (2015-2018) centered on specific disease mechanisms — cardiac hypertrophy treatment via beta3-adrenergic receptor agonists and digital tools for chronic disease self-management. From 2018 onward, their focus shifted decisively toward clinical trial infrastructure, paediatric drug development networks, and technology-enabled intensive care (AI telemedicine, remote monitoring). The trajectory shows a move from disease-specific basic-clinical research toward broader clinical trial ecosystems and digital health delivery platforms.

AIDFM is positioning itself as a clinical trial infrastructure partner with growing capability in digital health and telemedicine — expect them to seek projects combining clinical validation with remote monitoring technologies.

How they like to work

AIDFM operates exclusively as a consortium partner or third party — they have never coordinated an H2020 project. They participate in large consortia (175 unique partners across 24 countries), suggesting they are valued as a clinical site and medical research contributor within broad European networks. Their consistent participant role and wide partner base indicate they are a reliable, low-friction partner that integrates well into established consortium structures.

AIDFM has built a broad European network of 175 unique consortium partners spanning 24 countries, largely through health-focused Research and Innovation Actions. Their network reach is notably wide for an organization with only 7 projects, reflecting participation in very large consortia like c4c.

What sets them apart

AIDFM combines the clinical infrastructure of a major Lisbon medical faculty with hands-on experience in both traditional clinical trials and emerging digital health tools (AI telemedicine, cyberphysical systems, patient self-management apps). This dual capability — running conventional drug trials while also integrating digital monitoring technologies — makes them a strong partner for projects that need clinical validation sites with digital health literacy. Their c4c involvement (EUR 1.8M) also positions them as a key node in European paediatric clinical trial infrastructure.

Highlights from their portfolio

• c4c
  Their largest project by far (EUR 1.8M), building a pan-European collaborative network for paediatric clinical trials — signals deep investment in clinical trial infrastructure.
• ICU4Covid
  Demonstrates pivot into AI-driven telemedicine and cyberphysical systems for intensive care, showing capability beyond traditional clinical research.
• BETA3_LVH
  A rigorous multi-center randomized placebo-controlled trial testing a specific drug for cardiac hypertrophy — showcases their core clinical trial competence.